Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Glioblastomas (GBM) comprise 17% of all primary brain tumors. These tumors are extremely aggressive due to their infiltrative capacity and chemoresistance, with glial-to-mesenchymal transition (GMT) proteins playing a prominent role in tumor invasion. One compound that has recently been used to reduce the expression of these proteins is shikonin (SHK), a naphthoquinone with anti-tumor properties. Temozolomide (TMZ), the most commonly used chemotherapeutic agent in GBM treatment, has so far not been studied in combination with SHK. Here, we investigated the combined effects of these two drugs on the proliferation and motility of GBM-derived cells.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cell Oncol (Dordr)

Title: Cellular oncology (Dordrecht)

Publisher: Springer Nature

ISSN (Electronic): 2211-3436

ISSN (Print): 2211-3428

Publication date (Electronic): Jun 2017

Volume: 40

Issue: 3

Affiliations

[1 ] Brain's Biomedicine Laboratory, Paulo Niemeyer State Brain Institute, Secretaria de Estado de Saúde do Rio de Janeiro, Rua do Resende 156, Rio de Janeiro, 20231-092, Rio de Janeiro, Brazil.

[2 ] Institute of Biomedical Sciences at Federal University of Rio de Janeiro (ICB/UFRJ), Rio de Janeiro, 21941-902, Brazil.

[3 ] Center for Neuroscience and Cell Biology and Institute for Biomedical Imaging and Life Sciences (CNC.IBILI), Rua Larga Faculdade de Medicina, Pólo I, 1° andar, 3004-504, Coimbra, Portugal.

[4 ] Faculty of Medicine at University of Coimbra (FMUC), Pólo III - Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-354, Coimbra, Portugal.

[5 ] Hospital Center and University of Coimbra (CHUC), Praceta Prof. Mota Pinto, 3000-075, Coimbra, Portugal.

[6 ] Paulo de Góes Institute of Microbiology, Federal University of Rio de Janeiro, Rio de Janeiro, 21941-902, Brazil.

[7 ] Faculty of Pharmacy at University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal.

[8 ] Brain's Biomedicine Laboratory, Paulo Niemeyer State Brain Institute, Secretaria de Estado de Saúde do Rio de Janeiro, Rua do Resende 156, Rio de Janeiro, 20231-092, Rio de Janeiro, Brazil. vivaldomouraneto@gmail.com.

Article

Publisher Item ID: 10.1007/s13402-017-0320-1

DOI: 10.1007/s13402-017-0320-1

PubMed ID: 28401486

SO-VID: 7ce9c987-66e2-4a75-adaa-0f2ffcabd7cd

History

Keywords: Glial-to-mesenchymal transition,Glioblastoma,Migration,Shikonin,Temozolomide

Data availability:

Keywords: Glial-to-mesenchymal transition, Glioblastoma, Migration, Shikonin, Temozolomide

Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.

Read this article at

Abstract

Related collections

When did Helicobacter first colonise humans?

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 620

Cited by 15